Autolus Therapeutics (AUTL) announces the online publication of an abstract submitted to the American College of Rheumatology, ACR, Convergence 2025, to be held October 24-29, 2025, in Chicago. Autolus will have a poster presentation, which will include updated follow up from the CARLYSLE study in patients with severe refractory systemic lupus erythematosus, srSLE. Summary: Initial findings from the ongoing CARLYSLE study of obe-cel in srSLE show a manageable safety profile, with no dose limiting toxicities, immune effector cell-associated neurotoxicity syndrome or Grade greater than or equal to2 cytokine release syndrome. SLEDAI-2K score reduction and clinical benefit were observed in all patients. In addition, three patients who had a complete renal response. Updated data will be presented at the conference.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUTL:
- Autolus Therapeutics’ Earnings Call Highlights Growth and Challenges
- Autolus Therapeutics Reports Q2 2025 Financial Results
- Autolus Therapeutics: Strong Market Potential and Growth Opportunities Justify Buy Rating
- Autolus Therapeutics: Strong Q2 Performance and Strategic Growth Drive Buy Rating
- Autolus Reports Q2 2025 Financial Results